A small study, worth being aware of......
A randomized, placebo-controlled study of donepezil in poststroke aphasia
[Brief Communications]
Berthier, M L. MD, PhD; Green, C PhD; Higueras, C PhD; Fernández, I PhD; Hinojosa, J PhD; Martín, M C. PhD
Neurology Volume 67(9), 14 November 2006, pp 1687-1689
Abstract-
We studied 26 patients in a randomized, placebo-controlled, double-blind parallel trial to evaluate the efficacy and safety of donepezil in chronic poststroke aphasia. Donepezil (10 mg/day) improved aphasia severity at endpoint (week 16) relative to placebo (p = 0.037).
Donepezil has been shown to improve the severity of aphasia, motor aspects of speech, input-output phonology, and lexical-semantic processing.1,2 Moreover, a 6-month extension phase of an open-label trial of donepezil in poststroke aphasia (PSA) has demonstrated the persistence of beneficial effects.2 We report the results of a randomized controlled trial (RCT) of donepezil as an adjunctive treatment to standard speech-language therapy (SLT) in patients with chronic PSA.
<<Neurol (2006) - A randomized, placebo-controlled study of donepezil in poststroke aphasia.pdf>>
|